Compare · ABT vs IRD
ABT vs IRD
Side-by-side comparison of Abbott Laboratories (ABT) and Opus Genetics Inc. (IRD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABT and IRD operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABT is the larger of the two at $185.75B, about 473.4x IRD ($392.4M).
- Over the past year, ABT is down 15.1% and IRD is up 111.5% - IRD leads by 126.5 points.
- IRD has been more active in the news (15 items in the past 4 weeks vs 14 for ABT).
- ABT has more recent analyst coverage (25 ratings vs 14 for IRD).
- Company
- Abbott Laboratories
- Opus Genetics Inc.
- Price
- -
- -
- Market cap
- $185.75B
- $392.4M
- 1M return
- +6.51%
- -0.73%
- 1Y return
- -15.09%
- +111.46%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 14
- 15
- Recent ratings
- 25
- 14
Abbott Laboratories
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded in 1888 and is based in North Chicago, Illinois.
Latest ABT
- New Abbott Panbio™ COVID-19/Flu A&B Self-Test Helps Canadian Families Make Informed Decisions During Respiratory Illness Season
- EXECUTIVE VICE PRESIDENT Moreland Mary K sold $406,000 worth of Common shares without par value (3,500 units at $116.00), decreasing direct ownership by 3% to 100,791 units (SEC Form 4)
- SEC Form 10-Q filed by Abbott Laboratories
- Late-breaking one-year data show Abbott's next-generation Amulet 360™ device continues to demonstrate high rates of left atrial appendage closure and low incidence of stroke
- Abbott's TECTONIC clinical trial demonstrates strong 30-day outcomes and high procedural success for its investigational SonicForce™ Coronary Intravascular Lithotripsy System
- Abbott initiates pivotal trial for Cephea™ device, an innovative treatment for mitral heart valve disease
- Abbott Labs downgraded by Argus
- Abbott launches whole-genome sequencing Oncodetect® molecular residual disease (MRD) test to detect traces of cancer during and after treatment
- Abbott presents new ESMO data showing 30-percent absolute improvement in sensitivity with the whole-genome sequencing Oncodetect® test in colorectal cancer
- Nasdaq and Small Caps Lead Three Day Surge as Crude Slides and Blue Chips Hold Firm
Latest IRD
- Amendment: SEC Form SCHEDULE 13G/A filed by Opus Genetics Inc.
- SEC Form 10-Q filed by Opus Genetics Inc.
- Opus Genetics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Opus Genetics Announces Financial Results for Third Quarter 2026 and Provides Corporate Update
- Chief Executive Officer Magrath George sold $110,184 worth of shares (28,258 units at $3.90), decreasing direct ownership by 1% to 2,010,636 units (SEC Form 4) to satisfy withholding tax
- Opus Genetics Completes Dosing in Cohort 2 of Phase 1/2 Clinical Trial of OPGx-BEST1 Gene Therapy for Inherited Retinal Diseases
- Opus Genetics to Present at the Guggenheim Annual Healthcare Innovation Conference
- Opus Genetics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
- Opus Genetics Appoints Dr. Andrew Murphy as Chief Scientific Officer and Jamie Lynne Hart as Executive Director, Executive Operations
- Chief Operating Officer Schachle Joseph K sold $16,994 worth of shares (4,767 units at $3.57) (SEC Form 4)